慢性HBV携带者的临床识别与管理

Clinical identification and management of chronic HBV carriers

据世界卫生组织报道,每年约有65万人死于HBV感染所致的肝衰竭、肝硬化和肝细胞癌。尽管IFN及核苷和核苷酸类药物的应用在一定程度上降低了慢性乙型肝炎(CHB)不良结局的发生,但迄今为止,尚没有一种有效的治疗方法可以根除HBV。虽然HBV携带者不良结局的发生率明显低于慢性活动性CHB患者,但仍有发生肝硬化及肝癌的风险。针对如何识别HBV携带者及其管理等方面进行了论述,帮助临床进一步明确慢性HBV携带者的特征及治疗措施。

As reported by the world health organization,about 650 thousand people die of liver failure,liver cirrhosis,and hepatocellular carcinoma caused by hepatitis B virus（ HBV） infection every year. Although to a certain extent,the application of interferon and nucleos（ t）ide analogues reduces the adverse outcome of chronic hepatitis B（ CHB）,so far no effective therapeutic method can eliminate HBV. HBV carriers have a significantly lower incidence rate of adverse outcome than active CHB patients,but they still have the risk of progression to liver cirrhosis and liver cancer. This article discusses the clinical identification and management of HBV carriers,so as to further clarify the features of chronic HBV carriers and related treatment measures in clinical practice.